The stock of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is a huge mover today! About 310,445 shares traded hands. Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has risen 11.37% since April 5, 2016 and is uptrending. It has outperformed by 9.42% the S&P500.
The move comes after 5 months positive chart setup for the $351.84 million company. It was reported on Nov, 7 by Barchart.com. We have $11.94 PT which if reached, will make NASDAQ:ARWR worth $351.84 million more.
Analysts await Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to report earnings on December, 12. They expect $-0.37 EPS, up 11.90% or $0.05 from last year’s $-0.42 per share. After $-0.32 actual EPS reported by Arrowhead Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 15.63% negative EPS growth.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Ratings Coverage
Out of 3 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Arrowhead Research Corp has been the topic of 4 analyst reports since August 5, 2015 according to StockzIntelligence Inc. On Friday, September 25 the stock rating was maintained by Piper Jaffray with “Overweight”. The company was maintained on Wednesday, August 5 by RBC Capital Markets. Chardan Capital Markets initiated the stock with “Buy” rating in Thursday, May 19 report. On Friday, August 19 the stock rating was initiated by Cantor Fitzgerald with “Buy”.
According to Zacks Investment Research, “Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company’s proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.”
Insitutional Activity: The institutional sentiment decreased to 0 in 2016 Q2. Its down 0.54, from 0.54 in 2016Q1. The ratio fall, as 67 funds sold all Arrowhead Pharmaceuticals Inc shares owned while 0 reduced positions. 0 funds bought stakes while 0 increased positions. They now own 6,170 shares or 99.97% less from 18.16 million shares in 2016Q1.
The Manitoba – Canada-based Great West Life Assurance Can has invested 0% in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR). The Vermont-based Hanson Doremus Investment has invested 0% in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR).
Insider Transactions: Since August 22, 2016, the stock had 0 insider buys, and 1 sale for $160,000 net activity. Myszkowski Kenneth Allen sold $160,000 worth of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) on Monday, August 22.
Another recent and important Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) news was published by Marketwatch.com which published an article titled: “CORRECTED: mgen and Arrowhead Pharma agree 2 cardiovascular collaborations” on September 29, 2016.
ARWR Company Profile
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, incorporated on February 13, 2001, is a biopharmaceutical company. The Firm is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi therapeutics leverage this natural pathway of gene silencing to target and shut down specific disease causing genes. The Company’s products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. The Company’s ARC-520 is an RNAi therapeutic designed to treat chronic hepatitis B virus (HBV) infection by reducing the expression and release of new viral particles and viral proteins with the goal of achieving a functional cure for HBV. The Firm is conducting multiple Phase IIb clinical efficacy studies. The Company’s ARC-AAT is an unlocked nucleobase analog (UNA), which contains RNAi therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), a rare genetic disease that can damage the liver and lungs of affected individuals. The Firm is conducting a Phase Ib clinical trial for ARC-AAT. The study is a multi-center, randomized, placebo-controlled, double blind, single dose-escalation, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of ARC-AAT and the effect on circulating AAT levels.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.